News brief: operational changes and corporate events
Companies report updates on asset management, board changes, and new research results.
STMicroelectronics repurchases shares
Between October 12, 2026, and October 16, 2026, the company purchased 492,285 ordinary shares at a weighted average price of 42.95 EUR per share. The transaction totaled 21,145,480.12 EUR. The company currently holds 16,422,388 treasury shares, representing approximately 1.8% of its share capital.
Johnson & Johnson updates drug results
The company launched the Shockwave C2 Aero Fly coronary catheter, designed to reduce procedure times for treating coronary artery disease. Additionally, clinical data for the drug TREMFYA showed fistula remission in Crohn's disease patients increased to 35% by the 48th week of treatment.
Vale transfers mine management
The company completed a deal establishing Exiro Nickel Company as the new owner and operator of the Thompson Mine complex in Manitoba. Vale retained an 18.9% minority stake, while the remaining 81.1% belongs to other partners, including Exiro Minerals Corp and Canada Growth Fund.
AbbVie updates board of directors
On October 14, 2026, the company increased the size of its board of directors from twelve to thirteen members. Dr. John M. Carethers was appointed as a new independent director and joined the Public Policy and Sustainability Committee.
Casella Waste Systems to close landfill
The company announced that the NCES landfill in Bethlehem, New Hampshire, will stop accepting municipal solid waste starting December 31, 2026. The decision has been communicated to customers and regulators.
Original sources
- Casella Waste Systems Inc: 8-K filing, October 1, 2026
- AbbVie Inc.: 8-K filing, October 15, 2026
- STMicroelectronics N.V.: 6-K filing, October 19, 2026
- Johnson & Johnson announces new data showing TREMFYA® (guselkumab) is the only IL-23 to deliver durable fistula remission through 48 weeks in Crohn’s disease with perianal fistula
- Johnson & Johnson Launches Next-Generation Shockwave™ C2 Aero Fly Coronary IVL Catheter, Cutting IVL Treatment Time in Half
- Vale S.A.: 6-K filing, October 16, 2026
Cite this article
The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.
Alerts for your companies
The daily briefing as a notification in your browser or on your phone. Free, no email, no account, no app.
Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards
